Oslo, 13 December 2024

Reference is made to the announcement by Observe Medical ASA (the "Company" or
"Observe Medical", OSE ticker "OBSVR") on 5 December 2024 regarding the final
result of the subsequent offering in the Company, where a total of 2,303,933 new
shares were subscribed and allocated at a subscription price of NOK 0.40 per
share.

The share capital increase pertaining to the subsequent offering has today been
registered with the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret). The Company's registered share capital is NOK 64,477,175.62
divided into 247,989,137 shares, each with a nominal value of NOK 0.26.

The new shares will be issued in the Norwegian Central Securities Depository (ES
-OSL) on the listed ISIN NO 0010865009 and are expected to be delivered to the
respective subscribers' ES-OSL accounts later today on 13 December 2024.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.